Why Over-Screening Can Do More Harm Than Good

The intuition is hard to argue with. If catching cancer early saves lives, surely catching it even earlier saves more? If a colonoscopy every ten years is good, wouldn’t one every five be better?

Medicine has spent the last two decades quietly dismantling this logic. The answer, it turns out, is often no — and sometimes the reverse is true.

This isn’t a reason to avoid screening. It’s a reason to understand what screening actually does, and why the intervals are set the way they are.

The gap between finding something and helping someone

Screening works by looking for signs of disease before symptoms appear. The assumption is that earlier detection always leads to better outcomes. For some cancers — colorectal, cervical, breast — there’s strong evidence this is true, which is why organised screening programmes exist.

But there’s a category of findings that complicates this: things that look like disease, behave like disease on a scan or a test, but would never have caused a problem during the person’s lifetime. Pathologists call this phenomenon overdiagnosis — and it’s more common than most people realise.

Studies of thyroid cancer, for example, have found that rates of diagnosis have increased dramatically in countries that expanded screening — but death rates from thyroid cancer haven’t changed. Many of the cancers being found and treated were, in all likelihood, clinically irrelevant. The treatment — surgery, radiation, lifelong medication — carries its own risks. The person is left worse off than if the screening had never happened.

This isn’t a fringe view. The BMJ has published extensively on the phenomenon of “too much medicine,” and the Choosing Wisely initiative, developed by medical societies in multiple countries, was created specifically to address the problem of unnecessary tests and treatments.

What false positives actually cost

A false positive is a test result that suggests a problem where none exists. For screening tests applied to large populations, even a test with 95% accuracy will produce a false positive in 1 in 20 people tested. Screen frequently enough, and that number accumulates.

The consequences aren’t just administrative. A false positive mammogram leads to additional imaging, often a biopsy, and weeks or months of uncertainty while results are confirmed. A slightly elevated PSA triggers a referral, more tests, and in some cases treatment for a prostate cancer that was never going to cause symptoms.

Each of these follow-up procedures carries risk. Biopsies can cause bleeding or infection. Colonoscopies, performed more often than necessary, carry a small but real risk of bowel perforation. The cumulative effect of over-testing is not neutral — it adds up.

There’s also a psychological cost. Research has found that people who receive a false positive cancer screening result show elevated levels of anxiety and health-related worry for months, sometimes years, after the result is cleared. They’re more likely to re-present to healthcare services with unrelated symptoms. The experience of being told “we found something — it’s probably nothing, but we need to check” leaves a mark.

Screening and health anxiety

This is worth sitting with for a moment, because it runs counter to the message most health communication delivers.

Health anxiety — the persistent worry that one has or will develop a serious illness — is a recognised condition that affects a significant portion of the population. For many people, more frequent screening doesn’t reduce this anxiety. It feeds it. Each test becomes an opportunity for something to be found. Each clear result provides only temporary relief before the next test becomes overdue.

The evidence on this is nuanced. For people with genuinely elevated risk — strong family history, a genetic predisposition, a previous diagnosis — regular and sometimes frequent screening is the right call, and the reassurance it provides is real and evidence-based. But for average-risk individuals, pursuing screening beyond recommended intervals often reflects anxiety rather than medical necessity, and the tests themselves can entrench rather than resolve it.

This doesn’t mean concerns about health should be dismissed. It means that managing health anxiety through more testing isn’t always the right path — and a conversation with a doctor about what’s actually appropriate is more valuable than an extra scan.

Why intervals are set the way they are

The recommended gap between screenings isn’t arbitrary. It reflects a specific piece of biology: how long it takes for a detectable abnormality to progress to a stage where treatment makes a difference.

For colorectal cancer, polyps typically take 10 to 15 years to develop into cancer. That’s why guidelines recommend a colonoscopy every 10 years for average-risk adults with a normal result — not because ten years is a round number, but because that’s the window the biology gives you. Looking again at year five doesn’t catch more problems; it mostly finds the same normal colon again, at the cost of another procedure.

Cervical screening intervals follow a similar logic. HPV-related cell changes develop slowly. Testing too frequently picks up transient infections that the immune system would clear on its own — leading to unnecessary follow-up, treatment, and anxiety about a process that was self-resolving.

These intervals aren’t conservative estimates padded with caution. They’re the product of large-scale trials, modelling studies, and decades of outcomes data. When the USPSTF changed the recommended mammography start age in 2024, it wasn’t a casual revision — it reflected a re-analysis of the balance between early detection benefits and false positive harms across a large population.

What this means in practice

None of this is an argument against screening. It’s an argument for the right screening, at the right time, for the right person.

The practical implication is this: following evidence-based guidelines protects you better than either ignoring screening or going more often than recommended. Missing a scheduled colonoscopy is a problem. Booking one every three years because it feels safer is also a problem — just a less visible one.

If you’re unsure what’s appropriate for your situation — your age, your family history, your specific risk factors — that’s a conversation for your doctor, not a search query. Understanding the difference between screening and symptoms is also part of this: knowing when to act on a concern versus when to follow a routine schedule are different questions with different answers. Guidelines are population-level tools. Your doctor applies them to you individually.

What you can do without a doctor: know what’s due, know when you last had each check-up, and not let years drift by without realising it. That’s where the value of a simple tracking tool sits — not in telling you to screen more, but in making sure you don’t accidentally screen never. You can find answers to more common questions about screening in our FAQ.

Frequently Asked Questions

What is overdiagnosis in screening?

Overdiagnosis occurs when screening detects a condition — often a slow-growing cancer — that would never have caused symptoms or shortened the person's life. The condition is real, but treating it causes harm without benefit. It's most documented in thyroid cancer, prostate cancer, and some breast cancers, and it's one reason screening guidelines don't recommend testing everyone for everything.

Can too much health screening cause anxiety?

Yes. Research shows that false positive results — findings that turn out to be harmless — can cause elevated health anxiety for months or years after the result is cleared. For people already prone to health worry, frequent testing beyond recommended intervals can reinforce anxiety rather than resolve it. Evidence-based screening intervals are designed in part to balance early detection benefits against these psychological costs.

How do medical guidelines decide how often to screen?

Guidelines are developed by independent panels — such as the USPSTF in the US or the NHS in the UK — based on systematic reviews of clinical trial data, modelling studies, and outcomes research. They weigh the benefits of early detection against the harms of false positives, overdiagnosis, and procedure-related complications. The intervals they recommend reflect the biology of how conditions develop, not arbitrary caution.

Is it ever right to screen more often than guidelines recommend?

Yes — for people with elevated individual risk. If you have a strong family history of a particular cancer, a known genetic predisposition, or a personal history of a relevant condition, your doctor may recommend screening earlier or more frequently than population guidelines suggest. Guidelines are written for average-risk adults; they're a starting point, not a ceiling.

What's the difference between a false positive and overdiagnosis?

A false positive is a test result that incorrectly suggests disease where none exists — typically resolved with follow-up testing. Overdiagnosis is different: the disease is genuinely present, but it's one that would never have caused harm. Both can lead to unnecessary procedures and anxiety, but overdiagnosis is harder to identify because you can't know in advance which cancers would have remained harmless.